- Home
- TGL vs GRI Comparison
TGL vs GRI Comparison
Compare TGL & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGL
- GRI
- Stock Information
- Founded
- TGL 2020
- GRI 2018
- Country
- TGL United States
- GRI United States
- Employees
- TGL N/A
- GRI N/A
- Industry
- TGL Retail: Computer Software & Peripheral Equipment
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- TGL Technology
- GRI Health Care
- Exchange
- TGL Nasdaq
- GRI Nasdaq
- Market Cap
- TGL 4.1M
- GRI 4.8M
- IPO Year
- TGL 2022
- GRI N/A
- Fundamental
- Price
- TGL $1.08
- GRI $1.99
- Analyst Decision
- TGL
- GRI Strong Buy
- Analyst Count
- TGL 0
- GRI 2
- Target Price
- TGL N/A
- GRI $22.50
- AVG Volume (30 Days)
- TGL 5.8M
- GRI 3.4M
- Earning Date
- TGL 11-13-2025
- GRI 11-13-2025
- Dividend Yield
- TGL N/A
- GRI N/A
- EPS Growth
- TGL N/A
- GRI N/A
- EPS
- TGL N/A
- GRI N/A
- Revenue
- TGL $1,468,790.00
- GRI N/A
- Revenue This Year
- TGL N/A
- GRI N/A
- Revenue Next Year
- TGL N/A
- GRI N/A
- P/E Ratio
- TGL N/A
- GRI N/A
- Revenue Growth
- TGL N/A
- GRI N/A
- 52 Week Low
- TGL $0.70
- GRI $1.10
- 52 Week High
- TGL $61.50
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- TGL 46.32
- GRI 56.90
- Support Level
- TGL $1.05
- GRI $1.86
- Resistance Level
- TGL $1.23
- GRI $2.10
- Average True Range (ATR)
- TGL 0.10
- GRI 0.14
- MACD
- TGL -0.00
- GRI -0.01
- Stochastic Oscillator
- TGL 12.66
- GRI 52.23
About TGL Treasure Global Inc.
Treasure Global Inc has created an online-to-offline e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retailers/merchant settings. Its product is an internet application branded ZCITY app, that targets consumers by providing personalized deals based on consumers' purchase history, location and preferences.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.